Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up

Conditions

Idiopathic Pulmonary Fibrosis

Brief summary

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a high mortality. Health-related quality of life (HRQL) is impaired in patients with IPF. Little is known about the properties of recently developed HRQL questionnaires and about the longitudinal changes in HRQL, including factors with an impact on HRQL. Comorbidities have an impact on patients with IPF, but reports differ in incidence and prevalence. The impact of comorbidities on HRQL and disease progression has only been studied sparsely. Also, the association between biomarkers and disease progression need to be examined further.

Hansen AH, Breisnes HW, Prior TS, Hilberg O, Rasmussen DGK, Genovese F, Lukassen MV, Svensson B, Langholm LL, Manon-Jensen T, Karsdal MA, Leeming DJ, Bendstrup E, Sand JMB.

2023-06-195 citations

10.1016/j.clinbiochem.2023.110599

Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis.

Prior TS, Hoyer N, Hilberg O, Shaker SB, Davidsen JR, Bendstrup E.

2020-04-2125 citations

10.1186/s12931-020-01359-3

Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis.

Prior TS, Hilberg O, Shaker SB, Davidsen JR, Hoyer N, Birring SS, Bendstrup E.

2019-12-1925 citations

10.1186/s12890-019-1018-0

Validation of the IPF-specific version of St. George's Respiratory Questionnaire.

Prior TS, Hoyer N, Shaker SB, Davidsen JR, Yorke J, Hilberg O, Bendstrup E.

2019-08-2836 citations

10.1186/s12931-019-1169-9

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

1. A clinical diagnosis of IPF 2. Signed informed consent

Exclusion criteria

1. Clinical, radiological or histological findings inconsistent with a diagnosis of IPF 2. Inability or unwillingness to adhere to the study 3. Active on lung transplantation list

Design outcomes

Primary

Measure	Time frame	Description
Number and type of comorbidities	Baseline	Prevalence of comorbidities at baseline
Health-related quality of life	Baseline, 6 months, 12 months, 24 months, 36 months	Change in St. George's Respiratory Questionnaire

Secondary

Measure	Time frame	Description
Progression in serum/plasma biomarker levels	Baseline, 6 months, 12 months, 24 months, 36 months	Increase or decrease in serum/plasma biomarker levels
Lung function tests	Baseline, 6 months, 12 months, 24 months, 36 months	Change in forced vital capacity
Disease progression	Baseline, 12 months, 24 months, 36 months	Change in interstitial changes on high resolution CT-scan (HRCT)
Health-related quality of life	Baseline, 6 months, 12 months, 24 months, 36 months	Change in Short Form 36
6-minute walk test	Baseline, 6 months, 12 months, 24 months, 36 months	Change in 6-minute walk test

Countries

Denmark

Outcome results